Podcasts about dmd

This week, the Dental Amigos welcome Stephanie Mapp, DMD, dental consultant, speaker, and founder of “Mapp Your Practice.” With over 30 years of clinical and business experience, Dr. Mapp helps dentists navigate PPOs, practice transitions, and sustainable growth strategies. In this episode, Dr. Mapp shares her journey as a multi-practice owner navigating financial and legal adversity. With the knowledge gained from this experience, she now empowers dentists to rethink PPO participation, associate hiring, and practice profitability with clarity and resilience. To learn more about Dr. Mapp and ”Mapp Your Practice,” visit www.mappyourpractice.com. Listeners who want to reach Paul can do so at Paul@DentalNachos.com and those who want to reach Rob can do so at Rob@RMontgomery-law.com.

On this episode, hosts Casey Hiers and Jarrod Bridgeman tackle a topic many dentists would rather avoid: the unexpected death of a practice owner. They stress the critical need for proactive financial and estate planning, not just to protect your business but also to spare your loved ones from a complicated and stressful process.Jarrod and Casey emphasize the immense value of having a comprehensive team in place to manage both your personal and professional affairs. They share real-world examples of how their clients' foresight has protected their practices and families, ensuring a smooth transition during an otherwise difficult time. Tune in to learn how to secure your legacy and give your loved ones peace of mind.Interested in more info on how to: Earn More, Save More, and Retire EarlyUpcoming Tour Dates: Go to our EVENTS page for infoFacebook: Four Quadrants AdvisoryInstagram: @fourquadrantsadvisoryLinkedIn: Four Quadrants Advisory

The DMD is here! DAILY MIGS DOWNLOAD! Plus we chat all about the PHILLIES KAREN!

Nick White, DMD, of Lake Mary Pediatric Dentistry, shares insights on dealing with staff shortages and current trends in the dental industry. He discusses taking a hands-on approach to new technology and offers advice for success for emerging leaders in the DSO space.

Nick White, DMD, of Lake Mary Pediatric Dentistry, shares insights on dealing with staff shortages and current trends in the dental industry. He discusses taking a hands-on approach to new technology and offers advice for success for emerging leaders in the DSO space.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne," Barry Byrne, MD, chief medical advisor at the Muscular Dystrophy Association and director of the Powell Gene Therapy Center at the University of Florida, discusses newly published consensus guidelines from the MDA and Parent Project Muscular Dystrophy on the safe delivery and monitoring of gene therapy in Duchenne muscular dystrophy (DMD). Byrne explains the rationale behind convening a global panel of experts, emphasizing the need for standardized practices in patient selection, administration, and follow-up care as gene therapy becomes more widely available. He highlights the importance of expanded multidisciplinary teams—including hematology, cardiology, nephrology, and immunology—in managing immune-related safety concerns, with particular attention to monitoring liver inflammation and emerging strategies such as rapamycin use. In addition, Byrne outlines how these guidelines address real-world challenges around access, including geographic barriers, language considerations, and financial constraints, while underscoring their role in shaping future gene therapy approaches as additional therapies move through development. Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:00 – Why consensus guidelines were needed for gene therapy in DMD 2:10 – Top-line clinical considerations from the published recommendations 4:30 – Protocols for monitoring and managing adverse events, especially liver toxicity 6:30 – Neurology News Network 8:30 – Addressing health equity, language access, and financial barriers in gene therapy care 12:00 – How these recommendations may shape the future of DMD treatment The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Elijah Stacy, founder of Destroy Duchenne, speaks with Kevin Counterman, author of Breakfall, along with Buddy and Alan, about their new book. Breakfall is inspired by Kevin's late brother, Michael, and tells the story of Rudy and the Gallagher family, exploring themes of legacy, resilience, and the impact of Duchenne muscular dystrophy on the whole family.Learn More about Breakfall: https://breakfallbook.comWant to be on the podcast? Click here: https://www.destroyduchenne.org/podca…Learn more about the Destroy Duchenne Podcast here: https://www.destroyduchenne.org/podcastWebsite: https://www.destroyduchenne.orgSocial Media: Facebook:   / destroyduche.  .Instagram:   / destroyduch.  .Twitter: https://twitter.com/destroydisease?la...LinkedIn:   / dest.  .ABOUT DESTROY DUCHENNE PODCAST:A podcast telling the stories of those affected by a fatal muscle-wasting disease, Duchenne muscular dystrophy (DMD), that robs children of their ability to walk by the age of 11, the ability to raise their arms by their teenage years, and eventually their lives in their early 20s.Hosted by 24-year-old founder of the 501(c)3 nonprofit organization Destroy Duchenne, Elijah Stacy, who also suffers from Duchenne muscular dystrophy.The goal of the Destroy Duchenne podcast is very simple, yet ambitious: interview every person that has a relationship to Duchenne—people with Duchenne, parents, family members, friends, teachers, doctors—and tell their story to the world.Destroy Duchenne is a registered 501(c)3 nonprofit organization with the mission: to Complete the Cure for Duchenne muscular dystrophy by advancing medical technologies into human practice.Federal Tax ID: #82-3268952#Breakfall

This podcast series is meant to highlight influential voices and stories within the oral and maxillofacial surgery community. In this very special episode, we are honored to feature two OMS legends to celebrate the legacy and future of AAOMS. Join us for an intriguing conversation between AAOMS President, J. David Morrison, DMD, and  President-Elect, Robert S. Clark, DMD, as they share their experiences with our host Myron Tucker, DDS.

Send us a textArtificial Intelligence is the future of dentistry, and we're so excited to get the inside scoop straight from the source, Dr. Greg Wu of Mango Voice

Host Dr. Joel Berg speaks with Dr. Chelsea Fosse, Vice President of the AAPD Research and Policy Center (RPC) on the current hot topics in public health and how the RPC is working to make an impact. They delve into how pediatric dentistry can continue to lead the way among the other dental specialties and with our medical peers on care for those children and adults with disabilities and other special healthcare needs. Dr. Fosse also shares how AAPD members and other healthcare professionals can turn to the RPC for support with state-specific questions relating to Medicaid or other legislation. Guest Bio: Chelsea Fosse, DMD, MPH is the Vice President, Research & Policy Center at the American Academy of Pediatric Dentistry (AAPD). She is boarded in dental public health. Before shifting her career to work in oral health policy research, she worked as a general dentist treating adults with disabilities. At AAPD, Chelsea leads a team focused on Medicaid policy and program administration, evidence-based dental care, access to high quality and safe dental care, the pediatric dental workforce, and other contemporary issues in oral health, public health, and health policy. She was previously at the American Dental Association (ADA) Health Policy Institute (HPI) where she led policy analysis for issues related to Medicaid and studied the oral health workforce and the industry's response to the COVID-19 pandemic. Before dental school, she worked in the Division of Children with Special Needs at the American Academy of Pediatrics. She currently serves as President of the Board of Directors at Well Child Center, a community-based organization offering WIC, dental, and other social and health services in Elgin, IL. Chelsea received her bachelor's from The University of Texas in 2009, DMD from Rutgers in 2017, and MPH from Columbia University in 2019. She completed a general practice residency at Helen Hayes Hospital in 2018 and a dental public health residency at Jacobi Medical Center in 2020. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The DMD is here! Daly Migs Download! Also we chat about your first job!

The DMD is here! DALY MIGS DOWNLOAD! We also chat with Taryn's hitchhiker!

In our latest podcast, Dr. Schmidt talks with Mitch Gardiner, DMD, FAGD, focused on dental malpractice and the role of expert witnesses in civil court cases, with discussions about the qualifications and objectivity required of dental experts. The conversation covered key elements needed to prove negligence in dental cases, including standards of care and proper documentation of patient interactions and treatment plans. Dr. Gardiner provided advice for young dentists on maintaining high standards of care through continuous education and proper record-keeping. Dr. Gardiner is a full-time general dentist practicing in a multi-specialty office. A 1977 graduate of The University of Medicine and Dentistry of New Jersey, Dr. Gardiner served for three years as a dental officer in the Navy. He is a clinical instructor on the teaching faculty of the Rutgers School of Dental Medicine in the Department of Restorative Dentistry-Fixed Prosthodontics. He has over 25 years of experience in reviewing dental malpractice cases as an expert witness. Dr. Gardiner lectures and presents programs on issues of dental malpractice throughout the United States. He holds fellowships in the Academy of General Dentistry, American College of Dentists and International College of Dentists.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Gilgamesh Pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with Emraclidine in schizophrenia treatment. The biotech industry's IPO stalemate appears to be ending, with Lb Pharma planning an IPO to fund a phase III-ready schizophrenia asset. The FDA has pulled Valneva's chikungunya shot from the market due to safety concerns, and several obesity drugs have failed to make it to market. Meanwhile, Arnatar is working on advancing RNA therapies beyond silencing.In other news, the disappointment of oral obesity therapies is discussed, with Novo emerging as a leader in the field. Trials for Eli Lilly's Orforglipron and Viking Therapeutics' VK2735 were underwhelming, leading to increased interest in weight loss pills in low- and middle-income countries. Capricor Therapeutics plans to fight FDA rejection of its DMD cardiomyopathy treatment, while a study in JAMA contradicts claims of corruption in vaccine advisory committees. Updates on cancer, cell and gene therapy are also provided.Stay tuned for more updates and feel free to suggest topics for future coverage.

The DMD is here! Let's get ready and hit this Monday hard! Plus Taryn picked up a hitchhiker?!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA is pushing new guidelines for cancer trials, recommending overall survival as a primary endpoint. Capricor Therapeutics is asking the FDA to reconsider their rejection of a treatment for DMD cardiomyopathy with the return of Vinay Prasad. Rocket Pharmaceuticals' phase II trial has resumed after a patient death, and the Trump administration's tariffs and drug pricing policies are causing confusion in the pharmaceutical industry. Fedegari is now offering customized solutions for the bio/pharmaceutical industry. The American Academy of Pediatrics is recommending the COVID-19 vaccine for kids, and there are updates on various biotech developments. Opinion pieces discuss drug pricing and the viability of high-dose peptides.The American pharmaceutical industry has lost the trust of the people, with many viewing them as the 'bad guys' despite producing drugs in the U.S. for Americans. The industry faces challenges such as competition and changing regulations, with the Trump administration's trade policies adding to the confusion. Some companies are taking a platform strategy approach to drug development, using one molecule to target multiple diseases. Despite these challenges, there are opportunities for innovation and growth in the industry. Additionally, conflicts of interest in vaccine committees have been decreasing, and companies are making strategic moves such as forming partnerships and restructuring to adapt to the changing landscape. The industry continues to navigate uncertainty and seek ways to improve drug development and access for patients.

The DMD is here! And school is almost started!

Ep 333: Transforming airway health & smiles with MARPE featuring Dr. Svitlana Koval, DMD, MSc, BDSThis week on The Untethered Podcast™, Hallie welcomes back Dr. Svitlana Koval, Florida's leading provider of Miniscrew-Assisted Rapid Palatal Expansion (MARPE). Together, they explore the powerful connection between dental expansion, airway health, and facial balance covering MARPE and clear aligner mechanics, Hallie's personal experience with her children's treatment, timelines, post-care, and the transformative outcomes of a holistic approach.If this episode resonates with you, snap a screenshot of you listening and share it on your Instagram Stories! Tag Hallie @halliebulkin and @drsvitlanakoval to spread the word.In this episode, you'll learn:✔️ Clear Aligner (e.g., Invisalign) Journey and Airway Health✔️ Personal Experience with MARPE and Facial Asymmetry✔️ Understanding MARPE: Procedures and Techniques✔️ Comparing Traditional Expanders and MARPE✔️ Timeline and Procedures for Adult Expansion✔️ Understanding Bone Remodeling and Expansion Techniques✔️ Aesthetic Considerations in Orthodontic Treatment✔️ Timeline for Appliance Removal and Bone Fusion✔️ Impact of Expansion on Facial Structure✔️ Addressing Concerns with Mini Screws and TADs✔️ In-Office Procedure Insights and Patient Care✔️ Managing Asymmetries in Facial StructureRELATED EPISODES YOU MIGHT LOVEEp 263: Breathing Easy – Link Between Orthodontics, Speech & Health with Dr. Svitlana Koval & Tiffany ZilbermanEp 331: Inside My MARPE Journey with yours truly, Hallie BulkinABOUT TODAY'S GUESTI am so excited for you to meet Dr. Svitlana Koval! You can hang out with her over on Instagram and check out her practice at drssk.com.✨ FREE TRAINING ALERT – HAPPENING SEPTEMBER 8–10!If you're an SLP, OT, or student… you need to join me for the FREE 3-Day Pediatric Feeding Screening Training. Over 34,000 of your colleagues have done it — now it's your turn!Here's what you'll get when you sign up:4 hours on a certificate of completion (perfect for your renewal hours)My complete pediatric feeding screening packet — development chart, 50-symptom checklist, findings chart & referral formA chance to win one of FOUR full scholarships to the 12-week Feed The Peds® courseGrab your spot here → www.feedthepeds.com/trainingOTHER WAYS TO CONNECT & LEARN

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs enable read-through of premature stop codons to restore full-length protein production in genetic diseases. Fischer, whose daughter has Dravet syndrome, covers the company's lead programs in dilated cardiomyopathy and DMD, advantages over traditional gene therapy approaches, and the path to human proof-of-concept.

In this enlightening episode of the Living to 100 Club Podcast, Dr. Joseph Casciani welcomes Dr. Whitney Deitz, National Clinical Director of Aspen Dental. Together, they explore the powerful connection between oral health and cognitive decline. Dr. Deitz shares insights into how periodontal disease may increase the risk for Alzheimer's and dementia. Also discussed are the challenges of maintaining dental hygiene in individuals with reduced dexterity and the critical role of prevention throughout the lifespan. Listeners will learn about: The role of bacteria like P. gingivalis in periodontal disease and its potential link to dementia. The importance of maintaining oral health for dignity, pleasure, and overall well-being in later life. Practical dental care strategies for older adults and their caregivers, including tools like the Oral-B Genius and Callis Curve toothbrushes. How dry mouth, tooth loss, and limited mobility can all contribute to declining oral health and cognitive outcomes. Join us as we uncover why oral health isn't just about teeth – it's about quality of life, cognitive health, and healthy longevity. Mini Bio Whitney L. Deitz, DMD, is a practicing dentist and practice owner with Aspen Dental, serving communities in Owensboro, Madisonville, and Bowling Green, Kentucky. She also partners with offices in Hopkinsville and Paducah, Kentucky.  A 2015 graduate of the University of Kentucky College of Dentistry, Dr. Deitz received the Robert Henry Geriatric Dentistry Award for her dedication to geriatric oral care. She then completed a residency with focus on special populations and medically compromised patients.  She joined Aspen Dental in 2016 and has since become known for her commitment to comprehensive dental care and a patient-first approach. Her clinical expertise has been recognized at the 2024 Denobi Awards Gala, where she and her lab technician were honored for their contributions to dentistry. Specifically, Dr. Deitz helped set a global record by delivering the youngest-ever set of dentures to a then two-year-old. Her work inspired Aspen Dental to pursue a formal partnership with the National Foundation for Ectodermal Dysplasias, now known as The Smile Bridge by The Aspen Group. For Our Listeners Dr. Deitz' website: AspenDental.com

"My friends are toys. I make them. It's a hobby. I'm a genetic designer." This is a two part podcast covering the important factors is successful gene therapy and introduces the knowledge gained from other neuromuscular diseases and how it can be used to positively impact gene therapy in FSHD. In part 1, we focus on AAV serotypes, transgene constructs, immune responses, and delivery. We look into DMD gene therapy and how that can impact the current FSHD gene therapy programs. Check us out on the MyFSHD Youtube channel as well.

The DMD is here! And we wanna talk about all the things! Let's get it going!

The DMD is here! And we chat about what to pack to go to Austin. And we chat about Sturgis.

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny over the company’s transparency following multiple patient deaths. In this week’s episode of "The Top Line," we explore Sarepta’s brief standoff with the FDA over Elevidys, a short-lived marketing pause, and the regulator’s surprise reversal on the treatment. Fierce Pharma’s Fraiser Kansteiner and Angus Liu sit down with Fierce Biotech’s Gabrielle Masson to recap the story and discuss the broader implications the Elevidys saga may have for gene therapy, the FDA and the pharmaceutical industry. To learn more about the topics in this episode: Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy Sarepta, bowing to FDA pressure, pauses shipments of Duchenne gene therapy Elevidys FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death Roche won't throw in the towel after DMD gene therapy Elevidys' rebuff in Europe See omnystudio.com/listener for privacy information.

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.

The DMD is here! And we are playing music from all over the place for donations of $169!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Vinay Prasad's departure from CBER has analysts anticipating a more traditional successor, while GSK streamlines its pipeline and pledges billions in US investments. Susan Monarez is now the confirmed CDC director, and the top biopharma venture capital raises of H1 2025 are summarized. Despite challenges like layoffs and market fluctuations, GSK remains committed to investing in the US despite tariffs. Other headlines include Madrigal's potential $2 billion investment, Biogen and Eisai's Alzheimer's drug update, and Novo Nordisk's new leadership. Trilink Biotechnologies is offering self-amplifying RNA constructs for potential therapeutic advancements.AI biotech companies have secured substantial funding in the first half of 2025, with continued investment pouring into startups within the industry. The top five biopharma venture capital raises of this period are highlighted. There is confusion surrounding Ira's definition of 'drug,' potentially hindering companies from pursuing approval for new formulations and indications. Vinay Prasad's departure from the FDA's Center for Biologics Evaluation and Research, following controversies related to Sarepta, has raised concerns among developers. Despite challenges, four biotech companies are successfully launching their products independently.Over 260 million people are impacted by rare diseases, emphasizing the need for faster evidence generation through global real-world data. GSK's commitment to investing in the US, Merck's cost-cutting measures to support its launch schedule, and Novo Nordisk's new leadership are also highlighted. The FDA has updated regulations regarding Sarepta's DMD gene therapy, making it available for ambulatory patients. Adaptimmune anticipates significant staff reductions following a cell therapy asset sale. Stay tuned for more updates on the latest developments in the biopharma industry.

In the latest podcast, Dr. Schmidt talks with Ralph Cooley, DDS, FAGD, and Arlene O'Brien, DMD, FAGD, who are members of ADA Legislative and Government Affairs Council and AGD representatives to the ADA Code Maintenance Committee. The Code Maintenance Committee is responsible for reviewing and updating dental coding systems. In their roles, they advocate for changes that benefit general dentists. New codes for 2026 include updates to anesthesia codes, a new cracked tooth testing code, and modifications to denture duplication and occlusal guard cleaning codes. They emphasize the importance of public input and collaboration between organizations. Listen now.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk has announced Maziar Mike Doustdar as its new CEO, along with a 5% reduction in its 2025 sales guidance. This decision comes as a response to the slowed growth of its semaglutide franchise in the U.S. Senate Democrats are currently looking into HHS Secretary RFK Jr.'s controversial move to dismiss all 17 members of the CDC's vaccine advisory committee. Astrazeneca CEO Pascal Soriot emphasized the importance of global collaboration in pharmaceutical research and development. Merck has allocated $3 billion to support upcoming product launches. In a surprising turn of events, the FDA has reversed its decision on Sarepta, now permitting DMD gene therapy for ambulatory patients.

The DMD is here! And we chat about the staff's favorite OZZY and Black Sabbath songs!

Last week's public disclosure that a gene therapy from Sarepta had caused a third death led FDA to ask the company to stop distributing its DMD gene therapy Elevidys, a move the biotech has resisted. The deaths, and disputes between FDA and Sarepta, raise questions about the future of AAV gene therapies, as well as the future of FDA's platform technology designation. On the latest BioCentury This Week podcast, BioCentury's analysts unpack the events surrounding Sarepta's gene therapies and discuss how FDA, industry and patient groups should come together to learn the lessons from the tragic, avoidable deaths.BioCentury's analysts also assess Monday's appointment of Stanford professor and biotech executive George Tidmarsh to lead FDA's Center for Drug Evaluation and Research, and check in on the latest trends in venture financings. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656537#biotech #biopharma #pharma #lifescience #GeneTherapy #AAVTherapy #Sarepta #Elevidys00:01 - Sponsor Message: IQVIA Biotech02:03 - Gene Therapy17:59 - Leading CDER27:00 - Venture ReportTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

The DMD is here! Sounders tied. Mariners didn't play, and we talk calling people the wrong name!

The DMD is here! We love informing you! Plus let's chat about going to the zoo!

THE DMD is here! And we are ready to go! Cal Raleigh won the HOMERUN DERBY!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Takeda has taken the lead in the race for a narcolepsy treatment with back-to-back phase III wins for their drug Oveporexton. Investors are eagerly awaiting breakthroughs in using psychedelics to treat depression. Ultragenyx faced a setback as the FDA rejected their gene therapy for Sanfilippo syndrome, citing manufacturing issues. The FDA is considering speeding up reviews for companies that promise to lower drug costs. Market reaction to recent readouts from Compass Pathways and Beckley Psytech/Atai in treatment-resistant depression shows the challenges psychedelic therapies must overcome for commercial viability. Rainin Micropro offers a solution to streamline NGS preparation with their 96-channel pipettor. The industry is also focused on precision diagnostics to support precision therapeutics in the future. AstraZeneca's Baxdrostat showed promising results in lowering blood pressure in a phase III trial. The ADA revealed R&D priorities for potential blockbuster obesity treatments. Relmada has abandoned development of a depression drug after three failed attempts.The challenges faced by psychedelic therapies in the treatment of depression are discussed, as recent readouts from Compass Pathways and Beckley Psytech/Atai in treatment-resistant depression have left investors wanting more. The market reaction highlights the hurdles psychedelic therapies must overcome to prove their commercial viability. Additionally, the importance of precision diagnostics in the development of next-generation precision oncology therapies is emphasized, stating that only with the adoption of digital imaging and AI-powered analysis will these therapies reach their full potential. The FDA has several important decisions lined up, including applications in lymphoma, rare diseases, and hormone deficiency, while the American Diabetes Association's annual meeting reveals R&D priorities for weight loss medicines. Topics discussed include Capricor's FDA rejection of a DMD cell therapy, the ALS community petitioning the FDA to reconsider Brainstorm's Nurown, and updates on COVID-19 vaccines and Alzheimer's drugs. Upcoming webinars and job opportunities in the biopharma industry are also included.

The DMD is here! And we wanna chat with you about CAMPING!

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has rejected Capricor's therapy for Duchenne Muscular Dystrophy (DMD), causing shares to plunge due to insufficient evidence of effectiveness for cardiomyopathy associated with DMD. Lilly and Sarepta also received Complete Response Letters (CRLs) for their therapies. Moderna has won full approval for its COVID-19 vaccine for higher-risk kids, while Pacira has cut staff in San Diego. The FDA has released a cache of CRLs, providing insights into the journeys to market for various drugs. AbbVie has acquired Ichnos Glenmark's lead myeloma antibody, and Ultragenyx's stock plummeted after a late-stage trial disappointment. Kennedy postponed a preventive care panel meeting after a Supreme Court win. Transitioning from one piece of news to the next, let's move on to the webinar exploring digitization strategies for drug development. Stay tuned for more updates in the pharmaceutical industry.

Happy Thursday! The DMD is here and we are talking swear words! Plus donate now to Kicks for Kids at KISW.com!

THE DMD is here! Are you ready! Let's also chat about what you stole?

The DMD is here on a Tuesday! Plus we chat about rockstar names!

Happy Wednesday! The DMD is here! Let's chat about The Mariners losing.

The DMD is here! And let's chat about what your kid did for you!

The DMD is here! And we chat about role play!

In this episode of Talking Sleep, Drs. Michelle Cantwell and Aaron Glick discuss the updated American Academy of Dental Sleep Medicine (AADSM) Standards for Practice. Dr. Michelle Cantwell received her DMD through the University of Pittsburgh's School of Dental Medicine, where she also completed a three-year residency in prosthodontics. Following dental school, she served as a lieutenant commander in the US Navy. She is a diplomate of the ABDSM and the president-elect of the AADSM. She works in the pulmonary and sleep medicine department of WellSpan Health. Aaron Glick, DDS, FAGD, FICOI, D.ABDSM, is a dentist who has committed his practice to dental sleep medicine. He has been recognized as a “Top 10 Dentist to Watch” and works clinically utilizing teledentistry for efficient patient care. Dr. Glick educates fellow practitioners as the Mastery Program Director at the American Academy of Dental Sleep Medicine, focusing on mandibular advancement devices. Additionally, he is on the faculty at the University of Texas Health Science Center at Houston School of Dentistry. He actively lectures nationally and publishes on obstructive sleep apnea and technology. He enjoys all technologies and has a medical device and software programming background

DMD is here and we are ready to go!

The DMD is here! And we are ready to go on a hump day! Plus let's chat nick names!

Ep 324: Exploring Airway Health in Dentistry: Insights from Meggie Graham, DDS & Liz Turner, DMDThis week on the Untethered Podcast, Hallie welcomes Liz and Meggie from the Untethered Airway Health Center. They discuss the origins of their center and the importance of airway health in dentistry. Both Liz and Meggie dive into their personal journeys into airway-focused care and the establishment of their collaborative center. The conversation covers the holistic and interdisciplinary approach to treating tongue ties, the significance of pre and post-operative care, and how facial restrictions impact overall health. If this episode has resonated with you in some way, take a screenshot of you listening, post it to your Instagram Stories, and tag Hallie @halliebulkin and Meggie and Liz @untetheredairwayIn this episode, you'll hear:✔️ The origin of the Untethered Airway Health Center and its mission.✔️ Meggie's journey and collaboration with Liz.✔️ The importance of airway health in dentistry.✔️ Challenges in pediatric feeding and the role of myofunctional therapy.✔️ The value of comprehensive, interdisciplinary care.✔️ Cadaveric dissection and fascial connections.✔️ Identifying and treating airway issues in dentistry.✔️ The impact of orthodontics on airway health.✔️ Advocacy for children's health and educating providers and parents.✔️ New resources to advance airway health education.THIS WEEK:Doors to the Pediatric Feeding Hub are NOW OPEN! Get monthly mentorship from 5 experienced SLP and OT pediatric feeding specialists (plus the other members!) for a fraction of what a single consult would cost. https://pediatricfeedinghub.com/ LINKSGet to know Meggie Graham, DDS & Liz Turner, DMD on Instagram. Check out their website: https://untetheredairwayhealthcenter.com/aboutReady to turn your "myo eyes" on? Join our free training and learn how to screen patients for myo: https://www.feedthepeds.com/myo-webinarFind a myofunctional therapist here: www.themyodirectory.comConnect with Hallie on Instagram, Facebook & LinkedINHaven't left a review yet? Click here and thank you, as always, for being a listener! Want to watch more of the episode? Click here Hosted on Acast. See acast.com/privacy for more information.

Thursday is here! We got the DMD for you! And we chat about things you will always remember.

It's the DMD! And we are back from the Miles Montgomery Golf Tournament! Are we hungover? Probably. Also let's talk snakes!